Ligand-Independent Adenosine A2B Receptor Constitutive Activity as a Promoter of Prostate Cancer Cell Proliferation

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2016-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1124/jpet.115.230003PMID 26791603
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adenosine A2b receptor promotes progression of human oral cancer

  2015influential reference
• Expression of adenosine receptor subclasses in malignant and adjacent normal human prostate tissues

  2015cited by this paper
• Identification of Hypoxia-Inducible Factor HIF-1A as Transcriptional Regulator of the A2B Adenosine Receptor during Acute Lung Injury

  2014influential reference
• Pharmacology and Structure of Isolated Conformations of the Adenosine A2A Receptor Define Ligand Efficacy

  2013cited by this paper
• Adenosine A2B receptor-mediated VEGF induction promotes diabetic glomerulopathy

  2013cited by this paper
• A2B adenosine receptor blockade inhibits growth of prostate cancer cells

  2013influential reference
• Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma.

  2013cited by this paper
• Adenosine A2B receptor-mediated VEGF induction promotes diabetic glomerulopathy

  2013cited by this paper
• Adenosine A2B Receptor Blockade Slows Growth of Bladder and Breast Tumors

  2012cited by this paper
• Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells.

  2010influential reference
• Identification of Orthosteric and Allosteric Site Mutations in M2 Muscarinic Acetylcholine Receptors That Contribute to Ligand-selective Signaling Bias*

  2010cited by this paper
• Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening

  2010cited by this paper
• Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor.

  2009cited by this paper
• Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease.

  2009cited by this paper
• 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity.

  2009cited by this paper
• Host A(2B) adenosine receptors promote carcinoma growth.

  2008cited by this paper
• The adenosine a2b receptor: its role in inflammation.

  2008cited by this paper
• Structure-Function Studies of Allosteric Agonism at M2 Muscarinic Acetylcholine Receptors

  2007cited by this paper
• Inverse agonism: from curiosity to accepted dogma, but is it clinically relevant?

  2007cited by this paper
• Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery.

  2006cited by this paper
• Improving Potency, Selectivity, and Water Solubility of Adenosine A1 Receptor Antagonists: Xanthines Modified at Position 3 and Related Pyrimido[1,2,3‐cd]purinediones

  2006cited by this paper
• Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression.

  2005cited by this paper
• The hypoxic tumour microenvironment and metastatic progression

  2004cited by this paper
• Influence of receptor number on the cAMP response to forskolin in Chinese hamster ovary cells transfected with human beta2-adrenoceptor.

  2004cited by this paper
• Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective.

  2003cited by this paper
• The use of constitutively active GPCRs in drug discovery and functional genomics

  2002cited by this paper
• Mechanisms of inverse agonism at G-protein-coupled receptors.

  2002cited by this paper
• Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors

  2002cited by this paper
• International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.

  2001cited by this paper
• Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells.

  2001cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• Stochastic multidimensional hypercubes and inverse agonism.

  2000cited by this paper
• Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression

  2000cited by this paper
• Adenosine and cardioprotection during ischaemia and reperfusion – an overview

  2000cited by this paper
• Non‐competitive antagonism of β2‐agonist‐mediated cyclic AMP accumulation by ICI 118551 in BC3H1 cells endogenously expressing constitutively active β2‐adrenoceptors

  2000cited by this paper
• Constitutive activity of the d -opioid receptor expressed in C6 glioma cells: identification of non-peptide d -inverse agonists

  1999cited by this paper
• Constitutive activity of the delta-opioid receptor expressed in C6 glioma cells: identification of non-peptide delta-inverse agonists.

  1999cited by this paper
• Constitutive activity of the δ‐opioid receptor expressed in C6 glioma cells: identification of non‐peptide δ‐inverse agonists

  1999cited by this paper
• Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells.

  1999influential reference
• Leydig-cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor.

  1999cited by this paper
• Adenosine A2B receptors.

  1997cited by this paper
• Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins.

  1997cited by this paper
• Adenosine A2a and A2b receptors in cultured fetal chick heart cells. High- and low-affinity coupling to stimulation of myocyte contractility and cAMP accumulation.

  1995cited by this paper
• The two-state model of receptor activation.

  1995cited by this paper
• Brief report: congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene.

  1995cited by this paper
• Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands.

  1994cited by this paper
• Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins.

  1993cited by this paper
• Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing.

  1987cited by this paper
• PRESYNAPTIC RECEPTORS AND THEIR ROLE IN THE REGULATION OF TRANSMITTER RELEASE.

  1977cited by this paper
• The FASEB Journal • Research Communication HIF-dependent induction of adenosine A2B receptor in hypoxia

  year unknowninfluential reference

• Adenosine receptors on the immuno-oncology expressway: TIME, perspectives, and translation

  2026cites this paper
• Structure-based discovery of positive allosteric modulators of the A1 adenosine receptor

  2025cites this paper
• Overcoming multifaceted challenges in cancer treatment: Targeting signal transduction pathways and tumor microenvironment for enhanced therapeutic efficacy

  2025cites this paper
• Adenosine in Intestinal Epithelial Barrier Function

  2024cites this paper
• The different effects of four adenosine receptors in liver fibrosis

  2024cites this paper
• Transmembrane prostatic acid phosphatase: a therapeutic target in advanced prostate cancer.

  2024cites this paper
• Nanomaterial-enabled metabolic reprogramming strategies for boosting antitumor immunity.

  2024cites this paper
• Computational Characterization of Membrane Proteins as Anticancer Targets: Current Challenges and Opportunities

  2024cites this paper
• Synthesis, Anti-Proliferative Activity, DFT and Docking Studies of Some Novel Chloroquinoline-Based Heterocycles

  2023cites this paper
• Metabolic advantages of regulatory T cells dictated by cancer cells.

  2023cites this paper
• Canine Somatic Mutations from Whole-Exome Sequencing of B-Cell Lymphomas in Six Canine Breeds—A Preliminary Study

  2023cites this paper
• The adenosinergic machinery in cancer: In-tandem insights from basic mechanisms to therapy

  2023cites this paper
• Fighting in a wasteland: deleterious metabolites and antitumor immunity

  2022cites this paper
• Adenosine, Schizophrenia and Cancer: Does the Purinergic System Offer a Pathway to Treatment?

  2022cites this paper
• Identification of Phelligridin-Based Compounds as Novel Human CD73 Inhibitors

  2021cites this paper
• Expression and Gene Regulation Network of Adenosine Receptor A2B in Lung Adenocarcinoma: A Potential Diagnostic and Prognostic Biomarker

  2021influential citation
• Current Adenosinergic Therapies: What Do Cancer Cells Stand to Gain and Lose?

  2021cites this paper
• Purinergic signalling pathway: therapeutic target in ovarian cancer

  2020cites this paper
• Characterization of cancer-related somatic mutations in the adenosine A2B receptor.

  2020cites this paper
• CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers

  2020cites this paper
• Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker

  2020cites this paper
• 3,4-Dihydropyrimidin-2(1H)-ones as Antagonists of the Human A2B Adenosine Receptor: Optimization, Structure-Activity Relationship Studies, and Enantiospecific Recognition.

  2020cites this paper
• Implications of CD39 in immune-related diseases.

  2020cites this paper
• progress on adenosine A2B receptor and its role in related diseases

  2020influential citation
• Pharmacological Insights Into Safety and Efficacy Determinants for the Development of Adenosine Receptor Biased Agonists in the Treatment of Heart Failure

  2020cites this paper
• Adenosine A2A Receptor Antagonists for Cancer Immunotherapy.

  2020cites this paper
• Extracellular Vesicles Mediate B Cell Immune Response and Are a Potential Target for Cancer Therapy

  2020cites this paper
• Inhibition of the Adenosinergic Pathway in Cancer Rejuvenates Innate and Adaptive Immunity

  2019cites this paper
• NanoBRET ligand binding at a GPCR under endogenous promotion facilitated by CRISPR/Cas9 genome editing.

  2019cites this paper
• The adenosine A2B G protein-coupled receptor: Recent advances and therapeutic implications.

  2019cites this paper
• A2B Adenosine Receptor Antagonists with Picomolar Potency.

  2019cites this paper
• Inhibition of the adenosinergic pathway: the indispensable part of oncological therapy in the future

  2019cites this paper
• Therapeutic potentials of A2B adenosine receptor ligands: Current status and perspectives.

  2019cites this paper
• A2B Adenosine Receptor and Cancer

  2019cites this paper
• Small molecules as theranostic agents in cancer immunology

  2019cites this paper
• HIF-1α regulates A2B adenosine receptor expression in liver cancer cells

  2019cites this paper
• 1 A 2 B adenosine receptor and cancer 2

  2019cites this paper
• Adenosine receptor 2B activity promotes autonomous growth, migration as well as vascularization of head and neck squamous cell carcinoma cells

  2019cites this paper
• B-Zellen in der Kopf-Hals-Onkologie

  2018cites this paper
• Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer

  2018influential citation
• Tritium-labeled agonists as tools for studying adenosine A2B receptors

  2018cites this paper
• MRS1754 inhibits proliferation and migration of bladder urothelial carcinoma by regulating mitogen‐activated protein kinase pathway

  2018cites this paper
• Targeting Adenosine Receptor Signaling in Cancer Immunotherapy

  2018cites this paper
• Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment

  2018cites this paper
• Medicinal chemistry of a2B adenosine receptors

  2018cites this paper
• Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice

  2017cites this paper
• Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus

  2017cites this paper
• Role of adenosine in tumor progression: focus on A2B receptor as potential therapeutic target

  2017cites this paper
• Regulation of cannabinoid CB2 receptor constitutive activity in vivo: repeated treatments with inverse agonists reverse the acute activation of JNK and associated apoptotic signaling in mouse brain

  2017cites this paper
• Capadenoson, a clinically trialed partial adenosine A1 receptor agonist, can stimulate adenosine A2B receptor biased agonism

  2017cites this paper
• Adenosine A2B receptor: novel anti-cancer therapeutic implications

  2017cites this paper
• Targeting immunosuppressive adenosine in cancer

  2017cites this paper
• The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma

  2017cites this paper
• Adenosine A2B Receptor: From Cell Biology to Human Diseases

  2016cites this paper
• The hybrid molecule, VCP746, is a potent adenosine A2B receptor agonist that stimulates anti-fibrotic signalling.

  2016cites this paper
• Novel Irreversible Agonists Acting at the A1 Adenosine Receptor.

  2016cites this paper
• Extracellular Loop 2 of the Adenosine A1 Receptor Has a Key Role in Orthosteric Ligand Affinity and Agonist Efficacy

  2016cites this paper
• Role of adenosine A2b receptor overexpression in tumor progression.

  2016cites this paper
• DOTTORATO DI RICERCA IN AREA DEL FARMACO E TRATTAMENTI INNOVATIVI

  2016cites this paper